Atlas Trials

CYP2C19 Genotype-Specific Dosing Plus TDM on Reaching Therapeutic Voriconazole Blood Levels

Clinical trial NCT03731169 · COMPLETED

Trial details

NCT number
NCT03731169
Sponsor
University Health Network, Toronto
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Aspergillosis InvasiveFungal Infection
Start date
2018-01-10
Primary completion
2019-08-31
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.